45x Ab-conjugated beads (S5P6 - human IL-6 ab-bead). PN: A111179TA. One vial containing 35 µL of anti-human IL-6 conjugated to AimPlex Bead S5P6
25x Biotin-detection Ab (human IL-6 Biotin-dAb). PN: A111179TB. One vial containing 35 µL of biotinylated anti-human IL-6.
Lyophilized Standard Mix-Human Group 1 Panel A, 7-Plex. PN: HG10007. One vial containing lyophilized recombinant IFNγ, IL-2, IL-4, IL-6, IL-10, IL-17A, and TNFα. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits
STORAGE: 2-8 C in the dark.
IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
APPLICATION: Optimal antibody pair and antigen standard for assaying human IL-6. Can be multiplexed with other analytes in Human Group 1. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001T) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
For Research Use Only. Not for use in diagnostic procedures.
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 5 pg/mL
LLOQ: < 10 pg/mL
ULOQ: > 5,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Cross-reactivity of analytes in Human Group 1: Negligible
Sample volume: 15 µL/test
Interleukin-6 (Accession P05231) is a member of the interleukin cytokine family, though it displays some hormone-like properties that can affect many metabolic processes. IL-6 may act as a pro- or anti-inflammatory cytokine. It is primarily secreted by T-cells and macrophages to stimulate immune responses. It may be secreted during tissue damage or during bacterial infections. IL-6 is able to cross the blood-brain barrier. IL-6 supports the growth of B-cells and inhibits the proliferation of regulatory T-cells. It may also have the potential to improve anti-tumor activity in cancer immunotherapy.
Banks WA, Kastin AJ, Gutierrez EG. Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci. Lett. 1994; 179 (1-2): 53-56. Doi: 10.1016/0304-3940(94)90933-4.
Ferguson-Smith AC, Chen YF, Newman MS, May LT, Sehgal PB, Ruddle FH. Regional localization of the interferon-beta 2/B-cell stimulatory factor 2/hepatocyte stimulating factor gene to human chromosome. Genomics. 1988; 2(3): 203-208. Doi:10.1016/0888-7543(88)90003-1.
Jones SA, Takeuchi T, Aletaha D, Smolen J, Choy EH, McInnes I. Interleukin 6: The biology behind the therapy. BMJ. 2018; 2(1): Doi:10.1136/conmed-2018-000005.
Lin G, Wang J, Lao X, Wang J, Li L, Li S, Zhang J, Dong Y, Chang AE, Li Q, Li S. Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells. J Immunother. 2012; 35(4): 337-343. Doi: 10.1097/CJI.0b013e318255ada3.